U.S. flag

An official website of the United States government

NM_145298.6(APOBEC3F):c.1037A>G (p.Asn346Ser) AND not provided

Germline classification:
Benign/Likely benign (2 submissions)
Last evaluated:
Feb 1, 2023
Review status:
2 stars out of maximum of 4 stars
criteria provided, multiple submitters, no conflicts
Somatic classification
of clinical impact:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Somatic classification
of oncogenicity:
None
Review status:
(0/4) 0 stars out of maximum of 4 stars
no assertion criteria provided
Record status:
current
Accession:
RCV000954789.7

Allele description [Variation Report for NM_145298.6(APOBEC3F):c.1037A>G (p.Asn346Ser)]

NM_145298.6(APOBEC3F):c.1037A>G (p.Asn346Ser)

Gene:
APOBEC3F:apolipoprotein B mRNA editing enzyme catalytic subunit 3F [Gene - OMIM - HGNC]
Variant type:
single nucleotide variant
Cytogenetic location:
22q13.1
Genomic location:
Preferred name:
NM_145298.6(APOBEC3F):c.1037A>G (p.Asn346Ser)
HGVS:
  • NC_000022.11:g.39052610A>G
  • NM_145298.6:c.1037A>GMANE SELECT
  • NP_660341.2:p.Asn346Ser
  • NC_000022.10:g.39448615A>G
  • NM_145298.5:c.1037A>G
Protein change:
N346S
Links:
dbSNP: rs13056825
NCBI 1000 Genomes Browser:
rs13056825
Molecular consequence:
  • NM_145298.6:c.1037A>G - missense variant - [Sequence Ontology: SO:0001583]
Observations:
1

Condition(s)

Synonyms:
none provided
Identifiers:
MedGen: C3661900

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...

Assertion and evidence details

Submission AccessionSubmitterReview Status
(Assertion method)
Clinical Significance
(Last evaluated)
OriginMethodCitations
SCV001101448Invitae
criteria provided, single submitter

(Invitae Variant Classification Sherloc (09022015))
Benign
(Aug 14, 2018)
germlineclinical testing

PubMed (1)
[See all records that cite this PMID]

SCV004147901CeGaT Center for Human Genetics Tuebingen
criteria provided, single submitter

(CeGaT Center For Human Genetics Tuebingen Variant Classification Criteria Version 2)
Likely benign
(Feb 1, 2023)
germlineclinical testing

Citation Link

Summary from all submissions

EthnicityOriginAffectedIndividualsFamiliesChromosomes testedNumber TestedFamily historyMethod
not providedgermlineunknownnot providednot providednot providednot providednot providedclinical testing
not providedgermlineyes1not providednot providednot providednot providedclinical testing

Citations

PubMed

Sherloc: a comprehensive refinement of the ACMG-AMP variant classification criteria.

Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, Kobayashi Y, Patil N, Thusberg J, Westbrook M; Invitae Clinical Genomics Group., Topper S.

Genet Med. 2017 Oct;19(10):1105-1117. doi: 10.1038/gim.2017.37. Epub 2017 May 11. Erratum in: Genet Med. 2020 Jan;22(1):240-242.

PubMed [citation]
PMID:
28492532
PMCID:
PMC5632818

Details of each submission

From Invitae, SCV001101448.1

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not providednot providednot providednot providedclinical testing PubMed (1)
#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineunknownnot providednot providednot providednot providednot providednot providednot provided

From CeGaT Center for Human Genetics Tuebingen, SCV004147901.4

#EthnicityIndividualsChromosomes TestedFamily HistoryMethodCitations
1not provided1not providednot providedclinical testingnot provided

Description

APOBEC3F: BP4, BS2

#SampleMethodObservation
OriginAffectedNumber testedTissuePurposeMethodIndividualsAllele frequencyFamiliesCo-occurrences
1germlineyesnot providednot providednot provided1not providednot providednot provided

Last Updated: Apr 15, 2024